Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea

Cost Effectiveness and Resource Allocation

Volumn 16, Issue 1, 2018, Pages

  Lee, Donghoon ^a   Shin, Hyun Young ^b   Park, Sang Min ^c  

^a Kyung Hee University Hospital   (South Korea)

^b Hanyang Medical Center   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Antiviral prophylaxis; Cost effectiveness analysis; Hepatitis B; Perinatal infection

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B VACCINE;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DECISION TREE; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEPATITIS B; HUMAN; INFECTION PREVENTION; MEDICAL SOCIETY; MORTALITY RATE; PERINATAL INFECTION; PREGNANCY; PREVALENCE; PROGRAM COST EFFECTIVENESS; QUALITY ADJUSTED LIFE YEAR; SOUTH KOREA; VACCINATION; VERTICAL TRANSMISSION; VIRUS LOAD;

EID: 85042071532     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/s12962-018-0088-9     Document Type: Article

References (58)

1. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49:S45-55.
2. Chae HB, Kim JH, Kim JK, Yim HJ. Current status of liver diseases in Korea: hepatitis B. Clin Mol Hepatol. 2009;15(60):13-24.
3. Cheon JH, Park JW, Park WK, et al. The Clinical Report of 1078 cases of Hepatocellular carcinomas: National Cancer Center Experience. Clin Mol Hepatol. 2004;10(4):288-97.
4. Kim SR, Kudo M, Hino O, Han KH, Chung YH, Lee HS. Epidemiology of Hepatocellular carcinoma in Japan and Korea. Oncology. 2008;75:13-6.
5. Sim JG, Seo JK, Suh SJ. Prevalence and its changes of hepatitis B viral markers from 1988 to 1993 in Korean Children. Korean J Pediatr. 1995;38(11):1535-9.
6. Han BS, Kim IS, Suh I. A study of the seroconversion rates of anti-HBs and the duration of anti-HBs persistence after hepatitis B vaccination. Epidemiol Heal. 1989;11(2):215-31.
7. Korea Centers for Disease Control and Prevention. Korea Health Statistics 2015: Korea National Health and Nutrition Examination Survey (KNHANES VI-3). 2016.
8. Choe WH, Lee JS. Preventing vertical transmission of hepatitis B virus. Korean J Intern Med. 2014;87:557-64.
9. Korea Centers for Disease Control and Prevention. Guideline for the Perinatal Hepatitis B Prevention Program. 2017.
10. Kim J-H. The Appraisement of Perinatal Hepatitis B Virus Transmission Control Program in Republic of Korea. Korea Centers for Disease Control and Prevention 2011.
11. Chen H, Lin L, Hu F, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology. 2012;142(4):773-81.
12. Brown RS, McMahon BJ, Lok ASF, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. Hepatology. 2016;63(1):319-33.
13. Kim J-H, Choi EH, Park SE, et al. Recommended immunization schedule for children and adolescents: immunization Guideline (8th edition) released by the Korean Pediatric Society in 2015. Korean J Pediatr. 2016;59(12):461-5.
14. World Health Organization. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec. 2009;84(40):405-20.
15. Fan L, Owusu-Edusei K, Schillie SF, Murphy TV. Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection. Hepatology. 2016;63(5):1471-80.
16. Statistics Korea. Annual Report on Live Births and Deaths Statistics (Based on Vital Registration). 2014.
17. Klingler C, Thoumi AI, Mrithinjayam VS. Cost-effectiveness analysis of an additional birth dose of hepatitis B vaccine to prevent perinatal transmission in a medical setting in Mozambique. Vaccine. 2012;31(1):252-9.
18. Sonnenberg FA, Beck JR. Markov models in medical decision making a practical guide. Med Decis Mak. 1993;13(4):322-38.
19. Kim S-Y, Salomon JA, Goldie SJ. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. Bull World Health Organ. 2007;85:833-42.
20. Lu SQ, McGhee SM, Xie X, Cheng J, Fielding R. Economic evaluation of universal newborn hepatitis B vaccination in China. Vaccine. 2013;31(14):1864-9.
21. Tu HAT, de Vries R, Woerdenbag HJ, et al. Cost-effectiveness analysis of hepatitis B immunization in Vietnam: application of cost-effectiveness affordability curves in health care decision making. Value Heal Reg Issues. 2012;1(1):7-14.
22. Pan CQ, Duan Z, Bhamidimarri KR, et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol. 2012;10(5):452-9.
23. Wen W-H, Chang M-H, Zhao L-L, et al. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol. 2013;59(1):24-30.
24. Zanetti AR, Dentico P, Del Vecchio Blanco C, et al. Multicenter trial on the efficacy of HBIG and vaccine in preventing perinatal hepatitis B. Final report. J Med Virol. 1986;18(4):327-34.
25. Chen H, Lin L, Hu F, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology. 2012;142(4):773-81 (e2).
26. Wong VW, Reesink H, Ip HH, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin: double-blind randomised placebo-controlled study. Lancet. 1984;323(8383):921-6.
27. Wheeley SM, Jackson PT, Boxall EH, et al. Prevention of perinatal transmission of hepatitis B virus (HB V): a comparison of two prophylactic schedules. J Med Virol. 1991;35(3):212-5.
28. Sehgal A, Sehgal R, Gupta I, Bhakoo ON, Ganguly NK. Use of hepatitis B vaccine alone or in combination with hepatitis B immunoglobulin for immunoprophylaxis of perinatal hepatitis B infection. J Trop Pediatr. 1992;38(5):247-51.
29. Edmunds WJ, Medley GF, Nokes DJ, O'Callaghan CJ, Whittle HC, Hall AJ. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect. 1996;117(2):313-25.
30. Wiseman E, Fraser MA, Holden S, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust. 2009;190(9):489.
31. Zanetti AR, Magliano EM, Tanzi E, et al. HBIG immunoprophylaxis of babies born to HBsAg carrier mothers. Dev Biol Stand. 1982;54:383-9.
32. Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol. 2010;116(1):147-59.
33. Lee D, Shin HY, Park SM. Cost-effectiveness analysis of national Perinatal Hepatitis B Prevention Program. 2016.
34. Korea Centers for Disease Control and Prevention. Korea Health Statistics 2014: Korea National Health and Nutrition Examination Survey (KNHANES VI-2). 2015.
35. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA. 1995;274(15):1201-8.
36. Fan L, Owusu-Edusei K Jr, Schillie SF, Murphy TV. Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load. Obstet Gynecol. 2014;123(5):929.
37. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc R Soc Lond B. 1993;253:197-201.
38. Statistics Korea. Life Tables for Korea, 1970-2015. 2016.
39. Kim Y, Shin S, Park J, et al. Costing Methods in Healthcare. National Evidence-based Healthcare Collaborating Agency. 2013.
40. Kim J. Prevention of perinatal hepatitis B infection in high risk pregnant women through antenatal anti-viral agent. 2014.
41. Health Insurance Review & Assessment Service. Korea Pharmaceutical Information Service. https://www.hira.or.kr/rf/medicine/getSummaryList.do?pgmid=HIRAA030035010000. Accessed 27 October 2017.
42. Seong SC, Kim Y-Y, Khang Y-H, et al. Data resource profile: The National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2016;41:dyw253.
43. Statistics Korea. Korean Statistical Information Service (KOSIS).
44. Ock M, Lim SY, Lee H-J, Kim S-H, Jo M-W. Estimation of utility weights for major liver diseases according to disease severity in Korea. BMC Gastroenterol. 2017;17(1):103.
45. Aggarwal R, Ghoshal UC, Naik SR. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J Hepatol. 2003;38(2):215-22.
46. Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut. 2002;50(2):253-8.
47. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis c: risks, benefits, and costs. JAMA. 1998;280(24):2088-93.
48. Bae E-Y. Guidelines for economic evaluation of pharmaceuticals in Korea. J Prev Med Public Heal. 2008;41(2):80-3.
49. Bonneux L, Birnie E. The discount rate in the economic evaluation of prevention: a thought experiment. J Epidemiol Community Health. 2001;55(2):123-5.
50. Brouwer WBF, Niessen LW, Postma MJ, Rutten FFH. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ. 2005;331(7514):446-8.
51. Lee S, Chung W, Hyun K-R. Socioeconomic costs of liver disease in Korea. Korean J Hepatol. 2011;17(4):274-91.
52. Yoon J, Seo H, Oh IH, Yoon SJ. The non-communicable disease burden in Korea: findings from the 2012 Korean burden of disease study. J Korean Med Sci. 2016;31:S158-67.
53. Hung H-F, Chen H-H. Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B Virus infection. Pharmacoeconomics. 2011;29(12):1063-73.
54. Wang W, Wang J, Dang S, Zhuang G. Cost-effectiveness of antiviral therapy during late pregnancy to prevent perinatal transmission of hepatitis B virus. PeerJ. 2016;4:e1709.
55. Yang B-M, Kim DJ, Byun KS, Kim HS, Park J-W, Shin S. The societal burden of HBV-related disease: South Korea. Dig Dis Sci. 2010;55(3):784-93.
56. Statistics Korea. Annual Report on the Consumer Price Index. 2006.
57. Statistics Korea. Annual Report on the Consumer Price Index. 2014:1-8.
58. Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Heal. 2014;17(1):5-14.